NTRK Fusion Gene Positive Advanced Solid Tumor Market Share

Statistics for the 2023 & 2024 NTRK Fusion Gene Positive Advanced Solid Tumor market share, created by Mordor Intelligence™ Industry Reports. NTRK Fusion Gene Positive Advanced Solid Tumor share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Market Share of NTRK Fusion Gene Positive Advanced Solid Tumor Industry

The global NTRK Fusion Gene Positive Advanced Solid Tumor market is competitive and consists of a few major players. Companies like Bayer AG, Cephalon, Inc., Empire Genomics, LLC., Exelixis, Inc, F. Hoffmann-La Roche Ltd, NeoGenomics Laboratories, Inc., OncoDNA, among others, hold the substantial market share in the market.

NTRK Fusion Gene Positive Advanced Solid Tumor Market Leaders

  1. Bayer AG

  2. Empire Genomics, LLC

  3. F. Hoffmann-La Roche Ltd.

  4. NeoGenomics Laboratories, Inc.

  5. OncoDNA

*Disclaimer: Major Players sorted in no particular order

comp nfgpast.png

NTRK Fusion Gene Positive Advanced Solid Tumor Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)